2070009-55-9
2070009-55-9 結(jié)構(gòu)式
基本信息
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-19530 | 化合物 T12434 PF-2771 | 2070009-55-9 | 1 mg | 1136元 |
| 2026/06/05 | HY-19530 | 化合物 T12434 PF-2771 | 2070009-55-9 | 5 mg | 2500元 |
| 2026/06/05 | HY-19530 | 化合物 T12434 PF-2771 | 2070009-55-9 | 10 mM * 1 mL in DMSO | 3047元 |
常見問題列表
|
CENP-E 16.1 nM (IC 50 ) |
PF-2771 is a potent and selective CENP-E inhibitor, inhibiting CENP-E motor activity with an IC 50 of 16.1 nM. PF-2771 shows no inhibitory effect on the ATPase activities of highly related kinesins (0% inhibition of Eg5/KSP, chromokinesin, and MCAK at both 1 or 10 μM PF-2771). PF-2771 exhibits inactive activity against 74 protein kinases (all < 23% inhibition with 1 μM PF-2771, < 40% with 10 μM PF-2771). PF-2771 is cytotoxic to the basal-like breast cancer tumor cell survival, with EC 50 s of < 0.1 μM, and with no cytotoxicity on the normal and premalignant cell lines (EC 50 > 5 μM). PF-2771 (100 nM) reusults in a chromosomal congression defect in MDA-MB-468 cells.
PF-2771 (100 mg/kg, every day i.p.) potently inhibits CENP-E motor function, and causes tumor regression in SCID mice bearing AA1077 mammary tumors.